Assessment of AI Prediction Models in Prediction of Acute Kidney Injury in Critical Patients

Role of Artificial Intelligence in the Prediction of AKI in Critically Ill Patients

The assessment of AI -based prediction models in detecting AKI early in critically ill patients. Specifically, the aim is to evaluate the model's ability to predict the onset of AKI before it clinically manifests allowing for early interventions

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Kidney Failure; Artificial Intelligence (AI)

Detailed Description

Acute kidney injury (AKI) is the most severe, common, and life-threatening complication in hospitalized patients and is associated with high morbidity and mortality rates . It has been demonstrated that AKI affects approximately 30-60% of critically ill patients, especially those in the intensive care unit (ICU) . Despite the recent advances in clinical care and dialysis technology, the occurrence of AKI in ICU patients has a mortality rate of up to 50%, which is 1.5 to 2-fold to that of ICU patients without AKI . However, if detected and managed promptly, interventions guided by established recommendations, such as those provided by KDIGO, may mitigate the risk of further deterioration in AKI patients . Therefore, identifying individuals at high risk of AKI is vital for managing critically ill patients.

Artificial intelligence (AI) and machine learning (ML) represent emerging technologies that could use large amounts of health-related data to help physicians make better clinical decisions and improve individual health outcomes. While serum creatinine (Scr) and urine output serve as diagnostic criteria for AKI, delays in their detection may occur. Therefore, early identification of patients at risk of developing AKI is crucial to create a window for preventive interventions and mitigate the risk of further deterioration. Several previous studies have developed various ML-based models to predict AKI in critically ill patients due to the potential benefits of early detection of AKI . It is critical to remove the mystery surrounding ML since doing so makes it simpler for doctors to comprehend the reasoning behind ML . In order to explain why ML makes the choices it does, a new field called Explainable AI (XAI) has emerged. Two of the most popular methods for explaining are Local Interpretable Model-Agnostic Explanation (LIME) and Shapley Additive Explanation (SHAP) . Novel interpretable approaches have been effectively utilized to explain ML models for preventing hypoxemia during surgery [10], predicting mortality in sepsis and AKI , predicting the occurrence of AKI following cardiac surgery , and predicting antibiotic resistance .

To the best of our knowledge, the reliability and robustness of explanatory techniques for detecting AKI in critically sick patients have rarely been studied. Therefore, the present study was conducted to construct an ML approach for the early prediction of AKI in ICU patients and to apply XAIs to make ML more transparent and interpretable.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Kareem Sherif Mosabah, Assistant lecturer; Phone Number: +201002447880; Email: kareemsherif14@gmail.com
• Study Contact Backup: Name: Radwa Awad Abd El Hafez, lecturer; Phone Number: +201003797448; Email: radwaawad@aun.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Baseline characteristics, including demographic information, comorbidities, vital signs, laboratory results, medical interventions, disease severity scores, etc. were carefully reviewed and collected. The definitions of comorbidities including congestive heart failure, peptic ulcer disease, myocardial infarction, peripheral vascular disease, diabetes, dementia, chronic pulmonary disease, rheumatic disease, cerebrovascular disease, cancer, paraplegia, liver disease, renal disease, and acquired immunedeficiency syndrome. Severe organ failure due to ineffective immune response to infection was identified as sepsis. During the first 24 h when the patient was admitted to the ICU, the average values of the patient's vital signs (heart rate, mean arterial pressure, respiration rate, body temperature, and SpO2) were measured,, and the highest value of the biochemical laboratory tests (hematocrit, hemoglobin, platelets, white blood cell, blood urea nitrogen, international normalized ratio, Scr,

Description

Inclusion Criteria:

• All adult (aged 18 years old and older) patients who were admitted to the ICU were included in this study.

Exclusion Criteria:

• • patients under 18 years old

  • End-stage renal disease
  • Acute Kidney Injury at ICU admission
  • Inability to obtain sufficient clinical data

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The assessment of AI -based prediction models in detecting AKI early in critically ill patients.	assessment of the ability of the AI based model to detect AKI in critically ill patients by evaluating the model ability to predict the onset of early AKI before it is clinically manifested for early interventions . this will be done by generating an AKI risk score by the model for each patient. Outcomes are tracked and the model is updated periodically based on new patient data to improve accuracy and reliability	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
assessment of other aspects	assessment of clinical outcomes ( e.g, time to intervention , AKI severity , RRT use, and patient mortality ) impact on ICU (length of ICU stay)	1 year

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Study Director: Alaa El-Dein ElMoneim Sayed, professor, Assiut University

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Estimated): May 14, 2025
• Primary Completion (Estimated): March 1, 2026
• Study Completion (Estimated): March 1, 2026

Study Registration Dates

• First Submitted: February 26, 2025
• First Submitted That Met QC Criteria: February 26, 2025
• First Posted (Actual): March 4, 2025

Study Record Updates

• Last Update Posted (Actual): May 16, 2025
• Last Update Submitted That Met QC Criteria: May 14, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Acute Kidney Injury; Renal Insufficiency
• Other Study ID Numbers: AI role in AKI prediction

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No